RNA therapy company Ionis Pharmaceuticals Inc (Nasdaq: IONS) on Monday announced positive topline results from the Phase 3 Essence study of olezarsen in patients with moderate hypertriglyceridemia and at risk for atherosclerotic cardiovascular disease.

Olezarsen achieved the study's primary endpoint, delivering statistically significant reductions in triglyceride levels of 61% and 58% versus placebo at monthly doses of 80 mg and 50 mg, respectively (p